Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.71 USD | -0.21% | -0.61% | +26.43% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 533M |
---|---|---|---|---|---|
Net income 2024 * | -90M | Net income 2025 * | -111M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.01
x | P/E ratio 2025 * |
-4.7
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.7% |
Latest transcript on Astria Therapeutics, Inc.
1 day | -0.21% | ||
1 week | -0.61% | ||
Current month | +5.77% | ||
1 month | -10.18% | ||
3 months | -32.33% | ||
6 months | +116.26% | ||
Current year | +26.43% |
Managers | Title | Age | Since |
---|---|---|---|
Jill Milne
FOU | Founder | 56 | 08-06-25 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 11-03-31 |
Chief Tech/Sci/R&D Officer | - | 22-07-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 13-12-31 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 19-01-03 |
Director/Board Member | 75 | 16-04-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +3.39% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 9.71 | -0.21% | 561,758 |
24-05-10 | 9.73 | -4.33% | 443,655 |
24-05-09 | 10.17 | +6.27% | 677,955 |
24-05-08 | 9.57 | -4.11% | 630,353 |
24-05-07 | 9.98 | +2.15% | 420,278 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.43% | 533M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.30% | 21.93B | |
-12.15% | 22.34B | |
-5.38% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- ATXS Stock